Effects of varying antigens and adjuvant systems on the immunogenicity and safety of investigational tetravalent human oncogenic papillomavirus vaccines: results from two randomized trials (Q42221933)

From Wikidata

Jump to navigation Jump to search

scientific article published on 25 March 2014

Language	Label	Description	Also known as
English	Effects of varying antigens and adjuvant systems on the immunogenicity and safety of investigational tetravalent human oncogenic papillomavirus vaccines: results from two randomized trials	scientific article published on 25 March 2014

Statements

scholarly article

1 reference

Europe PubMed Central

18 October 2017

Effects of varying antigens and adjuvant systems on the immunogenicity and safety of investigational tetravalent human oncogenic papillomavirus vaccines: results from two randomized trials (English)

1 reference

Europe PubMed Central

18 October 2017

1 reference

based on heuristic

inferred from title

Geert Leroux-Roels

2

object named as

Geert Leroux-Roels

0 references

Pierre Van Damme

1

object named as

Pierre Van Damme

1 reference

Europe PubMed Central

18 October 2017

Jean-Michel Foidart

4

object named as

Jean-Michel Foidart

1 reference

Europe PubMed Central

18 October 2017

7

object named as

Myron Levin

1 reference

Europe PubMed Central

18 October 2017

author name string

Philippe Simon

3

1 reference

Europe PubMed Central

18 October 2017

Gilbert Donders

5

1 reference

Europe PubMed Central

18 October 2017

Karel Hoppenbrouwers

6

1 reference

Europe PubMed Central

18 October 2017

Fabian Tibaldi

8

1 reference

Europe PubMed Central

18 October 2017

Sylviane Poncelet

9

1 reference

Europe PubMed Central

18 October 2017

Philippe Moris

10

1 reference

Europe PubMed Central

18 October 2017

Francis Dessy

11

1 reference

Europe PubMed Central

18 October 2017

Sandra L Giannini

12

1 reference

Europe PubMed Central

18 October 2017

Dominique Descamps

13

1 reference

Europe PubMed Central

18 October 2017

Gary Dubin

14

1 reference

Europe PubMed Central

18 October 2017

language of work or name

0 references

publication date

25 March 2014

1 reference

Europe PubMed Central

18 October 2017

1 reference

Europe PubMed Central

18 October 2017

32

1 reference

Europe PubMed Central

18 October 2017

29

1 reference

Europe PubMed Central

18 October 2017

3694-3705

1 reference

Europe PubMed Central

18 October 2017

Human papillomavirus is a necessary cause of invasive cervical cancer worldwide

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.040

7 January 2021

Epidemiology and natural history of human papillomavirus infections and type-specific implications in cervical neoplasia

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.040

7 January 2021

Human papillomavirus type distribution in 30,848 invasive cervical cancers worldwide: Variation by geographical region, histological type and year of publication.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.040

7 January 2021

Classification of weakly carcinogenic human papillomavirus types: addressing the limits of epidemiology at the borderline

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.040

7 January 2021

Human papillomavirus types in 115,789 HPV-positive women: a meta-analysis from cervical infection to cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.040

7 January 2021

Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.040

7 January 2021

Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.040

7 January 2021

The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.040

7 January 2021

The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in sexually active women aged 16-26 years

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.040

7 January 2021

Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.040

7 January 2021

Development of an AS04-adjuvanted HPV vaccine with the adjuvant system approach

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.040

7 January 2021

Recent clinical experience with vaccines using MPL- and QS-21-containing adjuvant systems

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.040

7 January 2021

Correlation between direct ELISA, single epitope-based inhibition ELISA and pseudovirion-based neutralization assay for measuring anti-HPV-16 and anti-HPV-18 antibody response after vaccination with the AS04-adjuvanted HPV-16/18 cervical cancer vacc

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.040

7 January 2021

Reactivity of human sera in a sensitive, high-throughput pseudovirus-based papillomavirus neutralization assay for HPV16 and HPV18.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.040

7 January 2021

Comparison of the immunogenicity and safety of Cervarix and Gardasil human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18-45 years

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.040

7 January 2021

Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 vaccine and HPV-6/11/16/18 vaccine: follow-up from months 12-24 in a Phase III randomized study of healthy women aged 18-45 years

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.040

7 January 2021

Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.040

7 January 2021

Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.040

7 January 2021

Comparison of the immunogenicity of the human papillomavirus (HPV)-16/18 vaccine and the HPV-6/11/16/18 vaccine for oncogenic non-vaccine types HPV-31 and HPV-45 in healthy women aged 18-45 years

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.040

7 January 2021

A prospective, randomized, comparative US trial of a combination hepatitis A and B vaccine (Twinrix) with corresponding monovalent vaccines (Havrix and Engerix-B) in adults

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.040

7 January 2021

Can monovalent hepatitis A and B vaccines be replaced by a combined hepatitis A/B vaccine during the primary immunization course?

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.040

7 January 2021

Rapid and sustained immune response against hepatitis A and B achieved with combined vaccine using an accelerated administration schedule

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.040

7 January 2021

Reactivity pattern of 92 monoclonal antibodies with 15 human papillomavirus types

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.040

7 January 2021

Epidemiological study of anti-HPV16/18 seropositivity and subsequent risk of HPV16 and -18 infections

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.040

7 January 2021

HPV16/18 L1 VLP vaccine induces cross-neutralizing antibodies that may mediate cross-protection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.040

7 January 2021

Immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine administered as a 2-dose schedule compared with the licensed 3-dose schedule: results from a randomized study

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.040

7 January 2021

Proof-of-principle evaluation of the efficacy of fewer than three doses of a bivalent HPV16/18 vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.040

7 January 2021

Quantitative and qualitative analyses of serum antibodies elicited in adults by Haemophilus influenzae type b and pneumococcus type 6A capsular polysaccharide-tetanus toxoid conjugates

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2014.03.040

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/J.VACCINE.2014.03.040

1 reference

Europe PubMed Central

18 October 2017

1 reference

Europe PubMed Central

18 October 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q42221933&oldid=2076683366"